Tempest Therapeutics
TPST
16 hedge funds and large institutions have $6.67M invested in Tempest Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
0.02% less ownership
Funds ownership: 2.34% → 2.32% (-0.02%)
6% less capital invested
Capital invested by funds: $7.12M → $6.67M (-$446K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.08M |
| 2 |
Millennium Management
New York
|
+$40.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.9K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$38.6K |
| 2 |
Two Sigma Advisers
New York
|
-$34K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$26.3K |
| 4 |
Franklin Resources
San Mateo,
California
|
-$14.4K |
| 5 |
Morgan Stanley
New York
|
-$4.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EC
1
EcoR1 Capital
San Francisco,
California
| $2.22M | +$3.08M | +79,328 | New |
|
|
RSCM
2
Rock Springs Capital Management
Baltimore,
Maryland
| $1.77M | – | – | – |
|
3
Fidelity Investments
Boston,
Massachusetts
| $1.38M | – | – | – |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $534K | -$2.45K | -63 | -0.3% |
|
5
Fidelity International
Hamilton,
Bermuda
| $275K | – | – | – |
|
6
BlackRock
New York
| $178K | – | – | – |
|
|
IC
7
Ikarian Capital
Dallas,
Texas
| $132K | – | – | – |
|
|
8
Renaissance Technologies
New York
| $59K | -$38.6K | -992 | -32% |
|
|
9
Geode Capital Management
Boston,
Massachusetts
| $54K | -$26.3K | -677 | -25% |
|
|
10
Millennium Management
New York
| $29K | +$40.9K | +1,052 | New |
|
|
11
Franklin Resources
San Mateo,
California
| $23K | -$14.4K | -371 | -31% |
|
|
12
UBS Group
Zurich,
Switzerland
| $11K | +$14.9K | +384 | New |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $7K | +$2.6K | +67 | +40% |
|
|
14
Bank of America
Charlotte,
North Carolina
| $4K | +$3.3K | +85 | +121% |
|
|
15
Morgan Stanley
New York
| $1K | -$4.55K | -117 | -73% |
|
|
16
Two Sigma Advisers
New York
| – | -$34K | -777 | Closed |
|
TPST Hedge Fund Activity: Q2 2022 in Review
16 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2022, worth a combined $6.67M — down 6.3% from $7.12M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TPST positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 5 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $3.08M. The largest seller was Renaissance Technologies, cutting an estimated $38.6K.
- 16 institutional investors held Tempest Therapeutics (TPST) as of Q2 2022, up from 15 in Q1 2022.
- Funds reported $6.67M of Tempest Therapeutics stock for Q2 2022, down 6.3% quarter-over-quarter.
- 3 funds opened new Tempest Therapeutics positions in Q2 2022 and 2 closed out, a net change of +1 holder.
- The largest Tempest Therapeutics buyer in Q2 2022 was EcoR1 Capital, an estimated $3.08M added.
- The largest Tempest Therapeutics seller in Q2 2022 was Renaissance Technologies, an estimated $38.6K sold.
Based on aggregated 13F filings for Q2 2022.